New shot tested to tame lupus in kids
NCT ID NCT04179032
Summary
This study is testing a version of an existing lupus drug, belimumab, given as a shot under the skin (subcutaneous) in children aged 5 to 17. The main goals are to see if the drug reaches safe and effective levels in children's bodies and to monitor for side effects. Participants receive the injection along with their standard lupus care for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Berlin, 13353, Germany
-
GSK Investigational Site
Saint Augustin, 53757, Germany
-
GSK Investigational Site
Kagoshima, 890-8520, Japan
-
GSK Investigational Site
Kanagawa, 216-8511, Japan
-
GSK Investigational Site
San Luis Potosí City, 78213, Mexico
-
GSK Investigational Site
Rotterdam, 3015 GJ, Netherlands
-
GSK Investigational Site
Barcelona, 08950, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.